Activation of Foxo1 by Insulin Resistance Promotes Cardiac Dysfunction and β-Myosin Heavy Chain Gene Expression

Qi et al: Foxo1 Controls Cardiac Function and MHC Expression

Yajuan Qi1,2*, PhD; Qinglei Zhu1*, PhD; Kebin Zhang1, PhD; Candice Thomas1, PhD; Yuxin Wu1, PhD; Rajesh Kumar1, PhD; Kenneth M. Baker1, MD; Zihui Xu1, MD; Shouwen Chen1, PhD; Shaodong Guo1, PhD

1Division of Molecular Cardiology, Department of Medicine, College of Medicine, Texas A&M University Health Science Center, Baylor Scott & White Health, Central Texas Veterans Health Care System Temple, TX

2Department of Pharmacology, Hebei United University, Tangshan, China

* Equally contributed to the work

Correspondence to
Shaodong Guo
Division of Molecular Cardiology
Department of Medicine
College of Medicine
Texas A&M University Health Science Center
1901 South 1st Street, Bldg. 205
Temple, TX 76504
Tel: 254-743-1222 Fax: 254-743-0165
Email: sguo@medicine.tamhsc.edu

DOI: 10.1161/CIRCHEARTFAILURE.114.001457

Journal Subject Codes: [190] Type 2 Diabetes; [181] Signal Transduction
Abstract

Background—Heart failure is a leading cause of morbidity and mortality in the USA and is closely associated with diabetes mellitus. The molecular link between diabetes and heart failure is incompletely understood. We recently demonstrated that insulin receptor substrate 1, 2 (IRS1, 2) are key components of insulin signaling and loss of IRS1 and IRS2 mediates insulin resistance, resulting in metabolic dysregulation and heart failure, which is associated with downstream Akt inactivation and in turn activation of the forkhead transcription factor Foxo1.

Methods and Results—To determine the role of Foxo1 in control of heart failure in insulin resistance and diabetes, we generated mice lacking Foxo1 gene specifically in the heart. Mice lacking both IRS1 and IRS2 in adult hearts exhibited severe heart failure and a remarkable increase in the β-isoform of myosin heavy chain (β-MHC) gene expression, while deletion of cardiac Foxo1 gene largely prevented the heart failure and resulted in a decrease in β-MHC expression. The effect of Foxo1 deficiency on rescuing cardiac dysfunction was also observed in db/db mice and high-fat diet mice. Using cultures of primary ventricular cardiomyocytes, we found that Foxo1 interacts with the promoter region of β-MHC and stimulates gene expression, mediating an effect of insulin that suppresses β-MHC expression.

Conclusions—Our study suggests that Foxo1 has important roles in promoting diabetic cardiomyopathy and controls β-MHC expression in development of cardiac dysfunction. Targeting Foxo1 and its regulation will provide novel strategies in preventing metabolic and myocardial dysfunction and influencing MHC plasticity in diabetes mellitus.

Key Words: Forkhead transcription factor Foxo1; β-myosin heavy chain (β-MHC); insulin receptor substrate 1, 2; insulin resistance; diabetic cardiomyopathy
Heart failure is a clinical syndrome evidenced by decreased ability of the heart to provide sufficient cardiac output to support the normal functions of peripheral tissues, resulting from structural and functional impairment of ventricular filling or ejection of blood. Given the prevalence of type 2 diabetes mellitus and obesity, insulin resistance is a significant risk factor promoting cardiac dysfunction. Two-thirds of patients with type 2 diabetes have died of heart failure over the past decades. Diabetic cardiomyopathy was initially referred to as hyperglycemia-induced heart failure independent from hypertension and coronary artery diseases. Insulin is a primary and effective therapy to decrease hyperglycemia and reduce the risk of cardiovascular dysfunction in patients with type 1 diabetes. However, intensive insulin therapy lowers blood glucose levels; but, increases body weight and cardiovascular risk in patients with type 2 diabetes and hyperinsulinemia itself can result in insulin resistance. Thus, insulin resistance is recognized as an important mechanism for cardiac dysfunction. The molecular mechanisms of cardiac dysfunction from insulin resistance and/or diabetes include increased oxidative stress, altered substrate metabolism, mitochondrial dysfunction, activation of sympathetic nervous activity and the renin angiotensin system, and impaired calcium homeostasis, but the molecules responsible for insulin action, resistance and association with cardiac dysfunction are incompletely understood.

The heart is responsive to insulin that activates the insulin receptor on the cell membrane. The insulin receptor has tyrosine kinase activity and phosphorylates and recruits IRS1-4, and other scaffold proteins, including SHC, CBL, APS, SH2B, GAB1, and DOCK1, that trigger
downstream signaling cascades, including PI-3K and MAP kinases. Activation of PI-3K generates phosphatidylinositol (3,4,5)-triphosphate (PIP3), recruiting the 3-phosphoinositide dependent protein kinase-1 and -2 (PDK1 and PDK2) and Akt to the plasma membrane, where Akt is activated by PDK1-mediated phosphorylation at T^{308} and PDK2-mediated phosphorylation at S^{473}. Akt phosphorylates downstream targets, including inhibitors of macromolecular synthesis, such as glycogen synthase kinase-3β (Gsk3β, glycogen synthesis), tuberous sclerosis protein-2 (Tsc2) and p70S6K (protein synthesis), and forkhead transcription factor Foxo1 (gene transcription). Foxo1, a member of the forkhead/winged-helix transcription factor family, was first identified as an Akt substrate for phosphorylation. Akt phosphorylates Foxo1 at S^{253} and inhibits transcriptional activity of Foxo1, which regulates a variety of physiological functions, such as energy metabolism, autophagy, and myocardial growth.

Recently we have demonstrated that insulin receptor substrate 1, 2 (IRS1, 2) are major mediators of insulin in the activation of PI3K and Akt in mouse liver and heart. Loss of IRS1 and IRS2 in the liver resulted in hyperglycemia and hyperinsulinemia, and loss of IRS1 and IRS2 in the heart prevented endogenous PI3K and Akt activation, promoted Foxo1 activation, and resulted in cardiac failure. Moreover, reduced IRS1 and IRS2 gene expression and functionality and activation of Foxo1 are widely present in the heart of animals with insulin resistance or type 2 diabetes. Thus, loss of IRS1 and IRS2 and associated Akt inactivation and Foxo1 activation may provide a fundamental mechanism for insulin resistant cardiomyopathy. In
this study, we hypothesize that activation of Foxo1, following inhibition of IRS1 and IRS2, insulin resistance, and type 2 diabetes, has a central role in promoting cardiac dysfunction and expression of β-MHC gene, a heart failure marker involving cardiac contractile dysfunction.

Methods

Mice. All animal experiments were performed following procedures approved by the Texas A&M Health Science Center Institutional Animal Care and Use Committee. The floxed IRS1 mice (IRS1L/L), IRS2 mice (IRS2L/L), and Foxo1 (Foxo1L/L) were described previously. MHC-merCREmer, MHC-Cre, and db/+ mice were purchased from Jackson laboratory. All mice on a C57BL/6 and 129Sv mixed background were maintained on regular chow (Prolab Isopro 5P76). The high-fat diet (HFD) mice were fed with chow (Research Diet, D12451) up to 6 months, after 12-weeks of age. The HFD consists of 45% calories from fat, 25.6% carbohydrate, and 16.4% protein and the normal diet contains 11.4% fat, 62.8% carbohydrate, and 25.8% protein. For streptozotocin (STZ)-induced diabetes, adult male mice were intraperitoneally injected with STZ (50 mg/kg of body weight per day; Zanosar) for 5 consecutive days. Control mice were injected with the same volume of vehicle (0.1 mol/L sodium citrate). Male mice were used at the age of 1 to 8 months in all experiments, as indicated.

Chemicals and Antibodies. Insulin, wortmannin, PD98059, SP600125 and β-MHC antibody (cat#M8421) were purchased from Sigma. Antibodies against Foxo1 (cat# 9454), pFoxo1-
S256 (cat#9461), Akt (cat#9272), pAkt-S473 (cat#9271), and α-actinin (cat#6487) were from Cell Signaling Technology (Danvers, USA). IRS1 (cat#06-248) and IRS2 (cat#MABS15) were from EMD Minipore. Foxo1 antibody used for chromatin immunoprecipitation was from Santa Cruz Biotech Inc. (cat#sc11350, Dallas, USA).

**Echocardiography.** Echocardiograms were performed on anaesthetized mice using a VisualSonics Vevo® 2100 system, equipped with a 40 mHz linear probe. Left ventricular end-diastolic diameter (LVEDD) and left ventricular end-systolic diameter (LVESD) were measured from eight 2D short axis views of M-mode recordings, as we previously described. Fractional shortening (FS) was calculated as (LVEDD-LVESD)/LVEDD and expressed as a percentage.

**Electron Microscope.** Hearts were fixed in 2.5% formaldehyde/glutaraldehyde with 0.1 M sodium cacodylate buffer pH 7.4 overnight, followed by osmication and uranyl acetate staining, dehydration in alcohols and embedded in Taab 812 Resin (Marivac Ltd., Nova Scotia, Canada). 80 nm sections were cut with a Leica ultracut microtome, picked up on 300 mesh formvar/carbon coated Cu grids, stained with 0.2% lead citrate, and viewed and imaged under the Philips Technai BioTwin Spirit Electron Microscope, as we previously described.
Glucose and Insulin Measurements. Blood samples were collected from mice, blood glucose measured with a glucometer (Elite, XL, Byer), and serum analyzed for insulin, using a commercial kit (Crystal Chem., Inc.).

Protein Analysis and Western Blot. Tissue or cellular proteins were prepared, resolved by SDS-PAGE and transferred to nitrocellulose membrane for immunoblotting analysis, using specific antibodies and signal intensity measured and analyzed by NIH Image J software, as previously described 24.

Isolation and Cell Culture of Primary Cardiomyocyte and Cardiofibroblast (CFs). Primary cultures of neonatal rat ventricular cardiomyocytes (NRVMs) were prepared from hearts of 1- to 2-day-old Sprague-Dawley rat pups, as previously described 9.

Adenovirus Infection of Cardiomyocytes. NRVMs were cultured in DMEM/M199 medium with serum for 48 h, then transfected by adding adenovirus to the culture medium with a dose as indicated as MOI (multiplicity of infection). Cells were infected with adenovirus expressing green fluorescent protein (GFP) or GFP fused-Foxo1-wild type (WT), as previously described 9. After 8 h of infection, cells were changed to fresh medium with serum for 8 h and then serum starved for 8 h, prior to further treatment or collection of cell lysates.
RNA Isolation and Real-Time PCR Analysis. RNA from hearts or NRVMs was extracted with Trizol reagent (Invitrogen), cDNA synthesis utilized the SuperScript first-strand synthesis system (Bio-Rad), and quantity of cDNA for each transcript was measured using real-time PCR with the SYBER green supermix (Bio-Rad), and the primer sequences of PCR for α-MHC, β-MHC, Foxo1, and cyclophilin as previously described ⁹, ¹⁵.

Chromatin Immunoprecipitation (ChIP) assay. ChIP assay was performed as described previously ²³, ²⁵. Immunoprecipitated DNA was analyzed by PCR with primers specific to the promoters of the β-MHC gene: 5’-ACCATCTGACATTCTACAGTCT-3’ and 5’-AGAGCTCATCTTTCTGTGTCAT-3’.

Statistical Analysis. All results are presented as the mean ± SEM and analyzed by ANOVA to determine P values. P<0.05 was considered to be statistically significant, as previously described ⁹, ¹³. Freedom from cardiac death in mice was estimated by the Kaplan-Meier method and compared by the log-rank test.
Results

Generation of tamoxifen-inducible heart-specific IRS1, IRS2, and Foxo1 knockout mice

Deletion of both IRS1 and IRS2 genes in the hearts of mice (H-DKO mice) resulted in animal sudden death from heart failure, at the ages of 6 to 8 weeks, with cardiac Akt inactivation and Foxo1 activation. To further assess the role of Foxo1 activation in the adult hearts, we created mouse models of temporally regulated inactivation of IRS1 and IRS2, with or without Foxo1, in adult hearts. We crossed IRS1L/L::IRS2L/L and IRS1L/L::IRS2L/L::Foxo1L/L mice with transgenic mice expressing tamoxifen-inducible Cre-recombinase protein fused to two mutant estrogen-receptor ligand-binding domains under control of the α-MHC promoter (α-MHC-merCremer)26. In the resulting IRS1L/L::IRS2L/L/MerCre+ (H-DKO-merCremer) mice and IRS1L/L::IRS2L/L::Foxo1L/L/MerCre+ (H-TKO-merCremer) mice at the age of 10 weeks (Figure 1A), we administered tamoxifen daily for 5 days. We confirmed by immunoblot analysis that IRS1 and IRS2 protein expression was almost undetectable in the heart of both H-DKO and H-TKO (heart-specific triple IRS1, IRS2, and Foxo1 knockout) mice and that Foxo1 was reduced by 40% in H-TKO mice after the initiation of tamoxifen treatment (Figure 1B). The H-DKO hearts demonstrated diminished Akt-mediated Foxo1 phosphorylation at S253, indicative of Foxo1 activation, and strikingly enhanced the heart failure marker β-MHC gene expression, which is largely attenuated in H-TKO hearts (Figure 1B).
Lethal heart failure in H-DKO mice and rescue by Foxo1 deficiency in H-TKO mice

Without tamoxifen treatment, H-DKO-merCreEmer and H-TKO-merCreEmer mice survived and were indistinguishable in appearance from controls. Death of H-DKO-merCreEmer mice was observed beginning from 10 weeks after initiation of tamoxifen treatment. Kaplan-Meier analysis showed that the death event was significant higher in H-DKO mice than in H-TKO mice (log-rank test, \( p<0.05 \)). None of H-TKO-merCreEmer mice died after 24 weeks of tamoxifen treatment (Figure 1C).

Twenty four weeks after tamoxifen treatment, cardiac function of surviving H-DKO, H-TKO and control mice was analyzed by echocardiography. H-DKO mice had a significant reduction in EF, FS and LVPWs, and an increase in LVID-s/d, exhibiting a dilated cardiomyopathy (DCM), compared to controls (Table). However, H-TKO mice demonstrated significant improvement of cardiac function, even though cardiac ventricular mass was insignificantly improved, compared to H-DKO mice (Table). In H-DKO hearts, \( \beta \)-MHC, ANP, and BNP mRNAs were significantly increased, while myocardial Foxo1 deletion in H-TKO hearts, significantly reduced \( \beta \)-MHC mRNA and barely affected ANP and BNP mRNA levels (Figure 1D).

We further examined the cardiac ultra-structure of these mice. A well-organized morphology in sarcomeres, mitochondria, and Z-line is exhibited in control hearts (Figure 1E). However, H-DKO hearts exhibited enlarged sarcomeres, a loss of mitochondria and cristae of inner membranes. Strikingly, T-DKO hearts displayed nearly normal structures of sarcomeres and
Cardiac inactivation of Foxo1 rescues cardiac dysfunction in db/db and HFD mice

Foxo1 is persistently activated and mainly located in the nucleus of myocardium in db/db or HFD mice, and cardiac Foxo1 deficiency prevented cardiac dysfunction in HFD mice. To further examine whether cardiac Foxo1 deficiency improves cardiac function in db/db mice, we crossed Foxo1L/L mice with transgenic mice expressing a non-inducible Cre-recombinase under control of an α-MHC promoter, as we previously reported, generating heart-specific Foxo1 knockout mice (F1KO) mice. Breeding F1KO mice with db/+ mice, resulted in the generation of F1KO in db/db genetic background (Figure 2A). In addition, F1KO and control mice were fed with a high fat-diet (HFD) for 4 months prior to cardiac functional analysis.

Cardiac dysfunction in db/db and HFD hearts was clearly evident, compared to control heart, and the dysfunction was significantly improved by Foxo1 deficiency (Figure 2B, D): ejection fraction (EF) and fractional shortening (FS) were reduced in db/db hearts by 40% and 45%, respectively. However, ejection fraction (EF) and fractional shortening (FS) were only reduced by 10% and 8%, respectively, in db/db::F1KO mice compared to control hearts. Similarly, EF and FS were reduced by 32% and 38%, respectively, in HFD-hearts compared to control, while EF and FS were reduced by 15% and 10%, respectively, in HDF::F1KO mice (Figure 2B, D). RNA analysis indicated that β-MHC increased 2.8- and 12.3-fold in the hearts of db/db and HFD mice,
respectively, compared to control. However, cardiac Foxo1 deletion in db/db and HFD mice markedly decreased β-MHC expression (Figure 2C, E). Together, these results indicate that cardiac Foxo1 activation, following type 2 diabetes (db/db mice) or insulin resistance (HFD mice), significantly contributes to cardiac dysfunction, as well as increases β-MHC gene expression.

**Insulin deficiency increases β-MHC gene expression**

We hypothesize that β-MHC, the expression level of which is inversely proportional to cardiac contractility, is a target gene of insulin and Foxo1. We treated control and F1KO mice with streptozotocin (STZ), a compound known to destroy pancreatic β-cells and deplete insulin secretion, resulting in myocardial Akt inactivation. Without STZ treatment, both control and F1KO mice exhibited normal blood glucose and serum insulin levels, with a blood glucose of 110 ± 10 mg/dl and normal insulin level of 3.01 ± 0.2 ng/dl, in random-fed mice. However, 2 weeks after STZ treatment, hyperglycemia and hypoinsulinemia were observed in both control and F1KO mice, with a blood glucose level of 500 ± 35 mg/dl and insulin level of 0.015 ± 0.005 ng/dl (n=6, p<0.05 vs non-STZ group).

STZ treatment increased β-MHC gene expression by 6.8-fold in control hearts compared to the non-STZ treated group (Figure 3A), an effect which was attenuated in F1KO hearts, demonstrating an increase by 3.6-fold, compared to the non-STZ treated group (Figure 3A). Similar results were observed at the β-MHC protein level, as determined by Western blot (Figure
The results demonstrate that an increase of β-MHC expression in the hearts of mice with type 1 diabetes and that Foxo1 deficiency partially normalized β-MHC expression in hearts of type 1 diabetic mice. These results suggest that Foxo1 stimulates β-MHC gene expression at 2 weeks of STZ-treated hearts, prior to overt cardiac dysfunction that was evident 10 weeks after STZ treatment.

**Foxo1 deficiency decreases β-MHC gene expression in cardiac Foxo1 gene knockout mice**

We further examined whether Foxo1 regulates β-MHC gene expression at a physiological level. Since Foxo1 is phosphorylated at S253 and inactivated by insulin during the random-fed state in mice, in which the β-MHC mRNA changes in the hearts of control and F1KO mice were not evident (Figure 3A-B). Thus, we measured Foxo1 and β-MHC mRNA and protein levels in hearts of mice following an overnight fast, where Foxo1 is dephosphorylated and activated upon a lower amount of insulin in controls (0.38 ± 0.2 ng/dl). In F1KO hearts, Foxo1 mRNA and protein were decreased by 70% and 60%, respectively, compared to control hearts (Figure 4A, B). Likewise, β-MHC mRNA and protein levels were also decreased by 40% and 35%, respectively, while the α-MHC mRNA level was significantly increased by 31% in F1KO hearts (Figure 4A). The control and F1KO hearts did not exhibit significant differences in EF and FS and other cardiac parameters (Table). However, mRNA expression levels of ANP and BNP were significantly increased in the hearts of F1KO mice without cardiac dysfunction (Figure 4C and Table). The results suggest that Foxo1 is required for β-MHC expression in vivo.
**Foxo1 is required for insulin suppression of β-MHC expression**

We next determined whether myocardial β-MHC expression can be physiologically regulated during fasting and feeding conditions, through Foxo1 or insulin which is a major suppressor of Foxo1 via Akt activation. We examined the effect of overnight fasting, random-fed or insulin stimulation on β-MHC expression, in the hearts of control and F1KO mice. In control mice, hearts from overnight fasting animals had a nearly 2-fold or 1.6-fold increase of β-MHC mRNA and protein, respectively, compared to random-fed hearts (Figure 5A,C). Hearts with random-feeding and insulin stimulation demonstrated markedly increased Akt that inhibited Foxo1 by enhancing phosphorylation of S253, compared to hearts from fasting control mice (Figure 5B). In F1KO mice, the fasting-feeding regulation of β-MHC expression in the hearts was abolished and insulin administration had little effect on suppressing cardiac β-MHC expression (Figure 5D). These results suggest that Foxo1 is necessary for feeding or insulin, to suppress cardiac β-MHC gene expression.

**Insulin suppresses and Foxo1 stimulates β-MHC gene expression in cardiomyocytes**

We next examined whether β-MHC is a direct target gene of insulin, via Foxo1 regulation *in vitro*. Using primary cardiomyocyte NRVMs, we previously showed that insulin inhibited β-MHC mRNA levels. We next examined which insulin signaling pathway was involved in suppressing β-MHC expression in cardiomyocytes. Insulin decreased β-MHC mRNA levels by 40% in NRVMs, compared to non-treatment (Figure 6A). Pretreatment with the PI3K inhibitor
wortmannin completely blocked the inhibitory effect of insulin on β-MHC gene expression, while the ERK1/2 inhibitor (PD98059) and JNK inhibitor (SP600125) did not block the inhibitory effect of insulin. The stimulatory effect of insulin on α-MHC expression was completely blocked by the PI3K inhibitor.

To further assess the role of Foxo1 in regulating β-MHC expression in a cell-specific manner, NRVMs and cardiofibroblasts (CFs) were simultaneously isolated and infected with adenovirus expressing Foxo1 wild-type (wt) or control green fluorescent protein (GFP) and treated with or without insulin for 12 h. Overexpression of Foxo1-wt significantly increased β-MHC mRNA and protein levels by 2.2- and 1.5-fold, respectively, compared to control cardiomyocytes expressing GFP (Figure 6B-D). The stimulatory effect of Foxo1-wt on β-MHC, at both mRNA and protein expression levels, was completely suppressed by insulin treatment in cardiomyocytes (Figure 6B-D). However, the expression level of β-MHC in CFs was less than 2-3 % of that in NRVMs, and was irresponsive to insulin suppression or Foxo1 stimulation (Figure 6B). These data suggest that insulin suppresses β-MHC gene expression via a PI3K and Foxo1-dependent pathway in cardiac myocytes, rather than fibroblasts.

**Foxo1 interacts with the promoter region of the β-MHC gene**

We finally examined whether the promoter region of β-MHC has a consensus Foxo1 binding site. A region of 10 kb of mouse β-MHC promoter was analyzed with the ENSEMBL genome database and three consecutive copies of conserved Foxo1 binding sequence or insulin response
element (IRE) -CAAAACAAA were identified, located 9.0 kb upstream of the transcriptional initiation site, with consensus in rodent species (Figure 6E). To determine whether Foxo1 interacts with the promoter region of the β-MHC gene, chromatin IP experiments were performed, the results of which indicated that endogenous Foxo1 interacted with the consensus DNA sequence on the β-MHC promoter region (Figure 6F). Together, our data suggest that Foxo1 is an endogenous transcription factor that interacts with the promoter region of β-MHC for transcriptional activation.

Discussion

In this study, we present three important findings: 1) Foxo1 deficiency in the heart prevented the cardiac dysfunction in mouse models with insulin resistance (H-DKO mice) and type 2 diabetes (db/db mice), reducing the heart failure marker β-MHC gene expression; 2) Foxo1 activation stimulates β-MHC gene expression in cardiomyocytes and interacts with a Foxo1 binding site on the promoter region of β-MHC gene; and 3) β-MHC is a target of insulin signaling that suppresses its expression via PI3K activation, while hearts lacking Foxo1 demonstrate decreased β-MHC expression by 50% and the inhibitory effect of insulin or feeding is prevented.

In this study, we provide a new target gene of Foxo1, β-MHC, in cardiomyocytes, which may potentially contribute to reduction of cardiac contractility (Figure 7). Replacing all α-MHC by β-MHC in mice did not result in sudden death, but increasing cardiac β-MHC expression in vivo is maladaptive reducing myocardial contractility. In many forms of cardiac stress resulting from
diabetes, pressure overload, or aging, a transition from α- to β-MHC occurs and the shift from fast to slow isomyosin was disadvantageous under cardiac stress. Moreover, hypertrophied or aged hearts displayed insulin resistance, by reduced IRS1 tyrosine phosphorylation and associated PI3K activity, which may also activate Foxo1 and subsequently increase β-MHC gene expression. Thus, increasing β-MHC and decreasing α-MHC gene expression by IRS suppression and in turn Foxo1 activation, resulting from insulin resistance, may link metabolic and mechanic stresses for cardiac contractile dysfunction.

Foxo1 activation is suppressed by insulin that reduces β-MHC and increases α-MHC gene expression. A transient response of β-MHC gene expression is less than 2-fold, upon fasting and feeding conditions in normal hearts. However, the MHC homeostasis is largely disrupted upon Foxo1 activation when insulin deficiency or resistance occurs. Moreover, cardiac β-MHC gene expression is tightly controlled by developmental and hormonal factors and is species-dependent. During the fetal developmental period of rodent hearts, β-MHC is the principal isoform expressed in the ventricles when insulin is mostly absent; α-MHC, however, is the principal isoform expressed in adult animals when insulin dominates, to control energy homeostasis. Although a rise of circulating thyroid hormone shortly after birth is thought to suppress β-MHC and increase α-MHC gene expression, rodent hearts continue to mature to adulthood where β-MHC is re-expressed, accounting for 10-15% of the total MHC pool, likely owing to an increase in mechanical stress and insulin resistance. Moreover, activation of fetal genes such as β-MHC was observed in the failing human hearts, in which overexpression of Foxo1 has been reported.
Unlike mice, normal human adult ventricles express nearly 10% α-MHC on a background of 90% β-MHC, which is consistent with a lower heart rate (~70 vs 600 beats/min in mice). However, the distribution further shifts to 100% β-MHC in the failing heart \(^{36}\). Thus, manipulating MHC plasticity to suppress β-MHC is thought to be a strategy in preventing heart failure \(^{37}\), and we expect that targeting Foxo1 following insulin resistance or deficiency, may provide a novel mechanism suppressing fetal gene expression and improving cardiac dysfunction in failing and aged hearts.

Gene expression of cardiac MHC genes is controlled by a complex regulatory program, though few transcription factors regulating MHC gene expression have been identified \(^{35, 38}\). The β-MHC and α-MHC genes are 93% homologous and products of two distinct genes, situated in tandem, on mouse chromosome 2, providing an antithetical manner for expression of the genes \(^{35, 39}\). The β-MHC gene is located 4 kb upstream from α-MHC and the 4 kb of intergenic space is transcriptionally active \(^{35, 40}\). Myocardial deletion of Foxo1 reduced β-MHC and increased α-MHC gene expression, suggesting that Foxo1 has an important role in regulating cardiac MHC. Binding of Foxo1 to the promoter region of β-MHC stimulates activity, possibly by recruiting p300/CBP which contains histone acetylase activity, as observed for IGFBP-1 \(^{41}\). Alternatively, Foxo1 may act as a co-repressor for the α-MHC promoter, by recruiting transcriptional repressors and Foxo1 can recruit histone deacetylase or nuclear suppressor N-CoR to suppress gene expression \(^{42, 43}\).
Myocardial insulin resistance in H-DKO and db/db or HFD mice indicate that distinct cardiac remodeling may develop in type 2 diabetes. H-DKO mice did not develop cardiac hypertrophy as is often seen in type 2 diabetes, but rather displayed a dilated cardiomyopathy (DCM), indicating that loss of IRS1 and IRS2, which closely associate with inactivation of PI3K and Akt, promotes cardiac dysfunction and loss of ventricular mass. Other signaling is required for cardiac hypertrophy in type 2 diabetes and it is likely that activation of sympathetic nerve activity or the renin-angiotensin system may be involved in cardiac hypertrophy, which often co-exists with type 2 diabetes prior to heart failure and/or animal death, such as in db/db or HFD mice. Thus, the compensation of cardiac hypertrophic cardiomyopathy (HCM) was lost in H-DKO hearts. Regardless, that inactivation of Foxo1 significantly improved cardiac function and promoted survival of animals with either DCM (H-DKO) or HCM (db/db or HFD) underscores the key role of Foxo1 in promoting cardiac dysfunction upon insulin resistance (Figure 7). On the other hand, heart failure patients often have suppression of insulin release and action by an increase in catecholamine secretion. Clinically, insulin has been used to treat severe heart failure patients and catecholamine antagonists reduce morbidity and mortality from heart failure, partially by increasing pancreatic insulin release. Thus, activation of Foxo1 secondary to insulin deficiency, resistance, or other activation mechanisms via catecholamines, may significantly promote its expression and functionality resulting in a remarkable increase in β-MHC gene expression and cardiac contractile dysfunction.
In addition to the regulation of MHC plasticity, inactivation of PI3K and Akt through inhibition of IRS1 and IRS2 and activation of Foxo1, may provide a key mechanism for insulin resistant cardiomyopathy (Figure 7). Firstly, Foxo1 promotes loss of mitochondria by activating gene expression of hemeoxygenase-1 (Hmox-1), an enzyme that catalyzes heme degradation. Heme is an essential component of mitochondrial complex III and IV, as we identified in hepatocytes. The death of H-DKO mice was likely from heart failure secondary to mitochondrial abnormality and H-TKO largely normalized the mitochondrial morphology and function, similar to hepatocytes we observed previously. Secondly, Foxo1 promotes cell death and inhibits myocardial proliferation. Overexpression of Foxo1 in the heart resulted in premature death in mice. A significant increase in cell apoptosis was found in H-DKO hearts, which was nearly undetectable in H-TKO hearts (data not shown). Thirdly, Foxo1 has other target genes that may promote cardiac dysfunction. For example, we recently identified angiotensinogen as a Foxo1 target gene, which stimulates angiotensin II generation controlling blood pressure and cellular apoptosis. Finally, Foxo1 activation is involved in metabolic remodeling. It has been recently shown that cardiac inactivation of Foxo1 in HFD mice promotes animal survival by protecting cardiac function, in which a major mechanism is that Foxo1 inactivation enhances myocardial glucose utilization via increasing glucokinase gene expression. Of note is that Foxo1 activation can provide benefit under certain conditions, by increasing hepatic glucose production for survival or promoting cardioprotective autophagy when animals...
suffer from prolonged fasting \cite{15, 18, 49}. However, the unrestrained autophagy in cardiomyocytes lacking IRS1 and IRS2, can result in myocyte loss, heart failure and premature death \cite{50}.

In summary, we found that Foxo1 controls cardiac homeostasis and MHC plasticity, which is moderately, dynamically, and metabolically regulated by insulin signaling at a physiological level, a process which is markedly dysregulated upon insulin resistance. Thus, we believe that targeting Foxo1 and its regulatory system, may provide novel strategies for therapeutic intervention in preventing metabolic and myocardial dysfunction and in influencing MHC plasticity in patients with diabetes and associated heart failure.

**Acknowledgements**

This material is the result of work supported with resources and the use of facilities at the Central Texas Veterans Health Care System, Temple, Texas. This work is presented at the American Heart Association Annual Meeting of Scientific Sessions on November 15-19, 2014, Chicago, USA.

**Sources of Funding**

This work is supported by American Heart Association grant BGIA-7880040, American Diabetes Association grant JF-7-07-27 and 7-14-CD-09, Faculty Start-up Funds from the Texas A&M University Health Science Center College of Medicine, and NIH/RO1 DK095118 to S. Guo.
Disclosures

None.

References


Table. Echocardiographic parameters of H-DKO, H-TKO, and F1KO mice versus control mice

<table>
<thead>
<tr>
<th>Variable</th>
<th>CNTR (n=11)</th>
<th>H-DKO (n=10)</th>
<th>H-TKO (n=10)</th>
<th>CNTR (n=8)</th>
<th>F1KO (n=8)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>6 months after tamoxifen injection</td>
<td>4 months old</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BW (g)</td>
<td>37.2±4.3</td>
<td>39.4±4.2</td>
<td>37.0±2.1</td>
<td>29.1±1.5</td>
<td>27.3±1.8</td>
</tr>
<tr>
<td>HVW (mg)</td>
<td>122.8±4.4</td>
<td>104.9±5.8*</td>
<td>108.7±5.2*</td>
<td>125.2±10.3</td>
<td>128.2±1.1</td>
</tr>
<tr>
<td>HVW/BW (mg/g)</td>
<td>3.43±0.35</td>
<td>2.73±0.22*</td>
<td>3.07±0.21*</td>
<td>4.31±0.21</td>
<td>4.75±0.22</td>
</tr>
<tr>
<td>HVW/TL (mg/mm)</td>
<td>67.3±3.1</td>
<td>57.8±2.3*</td>
<td>60.8±2.1*</td>
<td>67.6±3.7</td>
<td>69.2±1.4</td>
</tr>
<tr>
<td>LVPW-s (mm)</td>
<td>0.91±0.07</td>
<td>0.82±0.11*</td>
<td>0.82±0.07*</td>
<td>0.94±0.05</td>
<td>0.96±0.08</td>
</tr>
<tr>
<td>EF (%)</td>
<td>53.80±3.74</td>
<td>42.58±4.44*</td>
<td>48.44±4.28*</td>
<td>59.49±8.31</td>
<td>56.83±9.97</td>
</tr>
<tr>
<td>FS (%)</td>
<td>27.56±2.46</td>
<td>20.27±2.56*</td>
<td>23.92±2.51*</td>
<td>31.60±5.48</td>
<td>29.75±6.96</td>
</tr>
<tr>
<td>CO (ml/min)</td>
<td>18.75±1.55</td>
<td>12.58±1.67*</td>
<td>16.01±2.60*</td>
<td>17.66±1.00</td>
<td>16.80±4.14</td>
</tr>
<tr>
<td>LVID-s (mm)</td>
<td>2.72±0.30</td>
<td>3.20±0.29*</td>
<td>3.00±0.19</td>
<td>2.77±0.18</td>
<td>2.83±0.21</td>
</tr>
<tr>
<td>LVID-d (mm)</td>
<td>3.68±0.38</td>
<td>4.06±0.38</td>
<td>3.74±0.27</td>
<td>3.72±0.13</td>
<td>3.87±0.21</td>
</tr>
<tr>
<td>MV Decl (ms)</td>
<td>19.94±0.92</td>
<td>21.59±3.86*</td>
<td>19.11±3.20*</td>
<td>20.88±1.54</td>
<td>21.59±1.77</td>
</tr>
<tr>
<td>IVRT (ms)</td>
<td>18.30±1.75</td>
<td>21.08±1.30*</td>
<td>19.34±1.26*</td>
<td>16.85±3.11</td>
<td>17.52±0.73</td>
</tr>
<tr>
<td>E/A</td>
<td>1.56±0.12</td>
<td>1.35±0.08*</td>
<td>1.55±0.19*</td>
<td>1.74±0.05</td>
<td>1.68±0.04</td>
</tr>
<tr>
<td>MV E/E'</td>
<td>45.11±5.31</td>
<td>55.42±4.62*</td>
<td>42.69±6.72*</td>
<td>45.57±8.31</td>
<td>49.84±1.57</td>
</tr>
</tbody>
</table>

BW, body weight; HVW, heart ventricular weight; TL, tibial length; EF, ejection fraction; FS, fractional shortening; CO, cardiac output; LVPW-s: left ventricular posterior wall thickness at systole; LVID-s, left ventricular internal dimension at systole; LVID-d, left ventricular internal dimension at diastole; MV Decl, mitral valve E wave deceleration time; IVRT, isovolumic relaxation time; MV E/E’, ratio of mitral valve E velocity to E’ velocity; E/A, ratio of early and late ventricular filling velocity. Unless noted, otherwise in the text, measurements come from male mice. Values are mean ± SEM, * P<0.05 versus control mice; ^ P<0.05 versus H-DKO mice.
Figure Legends

Figure 1. Cardiac function and MHC gene expression in H-DKO mice lacking cardiac IRS1 and IRS2 and H-TKO mice lacking cardiac IRS1, IRS2, and Foxo1. (A) Strategies for generation of H-DKO and H-TKO mice. (B) Western-blot analysis of protein from hearts. Seven days after mice were treated with tamoxifen, hearts were collected and protein prepared and analyzed using antibodies against IRS1, IRS2, Foxo1, pFoxo1-S253, β-MHC, and α-actinin. Data from two different mice per group are shown. (C) Kaplan-Meier curves for survival of H-DKO and H-TKO mice (n=16 male mice per group). (D) Expression of heart failure maker genes in hearts of mice following 6 months of tamoxifen treatment in control, H-DKO and H-TKO mice. Values represent the mean ± SEM. n=6-8, *P<0.05 vs control; # P<0.05 vs H-DKO. CNTR refers to control (triple floxed and Cre mice). (E) Ultra-structures of hearts analyzed by Electron microscopy. Heart sections from control, H-DKO, and H-TKO mice following 6 months of tamoxifen treatment were prepared. Representative images of hearts with scale bars for 500 nm and 100 nm are shown.

Figure 2. Cardiac function and MHC expression in db/db and HFD mice lacking cardiac Foxo1. (A) Strategies for generation of db/db mice lacking cardiac Foxo1 gene. (B) Echocardiographic analysis of 8-month-old control, db/db, and db/db:: F1KO mice. Values represent the mean ± SEM. n=8, *P<0.05 vs control; # P<0.05 vs db/db. (C) mRNA levels of
hearts isolated from 8-month-old random-fed controls, \( db/db \) and \( db/db::F1KO \) mice. Values represent the mean ± SEM, \( n=8 \), *\( P<0.05 \) vs control; # \( P<0.05 \) vs \( db/db \) mice. (D) Echocardiographic analysis of 8-month-old control, HFD, F1KO, and HFD::F1KO mice. Values represent the mean ± SEM. \( n=8 \), *\( P<0.05 \) vs control; # \( P<0.05 \) vs F1KO. (E) mRNA levels of hearts isolated from 8-month-old random-fed control, HFD, F1KO, and HFD::F1KO mice. Values represent the mean ± SEM, \( n=6 \), *\( P<0.05 \) vs control; # \( P<0.05 \) vs F1KO.

**Figure 3.** MHC gene expression in mice lacking cardiac Foxo1 gene (F1KO) with type 1 diabetes. (A-B) 2 weeks after STZ treatment and non-STZ treatment, mRNA and protein were isolated from hearts of 10 week-old random-fed control and F1KO mice. The mRNA expression of β-MHC and α-MHC was analyzed by real-time PCR (A) and protein expression of β-MHC by Western-blot (B). Values represent the mean ± SEM, \( n=4 \), *\( P<0.05 \) vs CNTR; #\( P<0.05 \) vs CNTR+STZ. Representative results of Western-blots from hearts of 2 mice in each group are shown in B.

**Figure 4.** Cardiac β-MHC gene expression in mice lacking cardiac Foxo1. (A) mRNA and protein expression of β-MHC (B) in hearts of 10 week-old F1KO mice, following an 18 h fast. Values are expressed as the mean ± SEM, \( n=6-8 \), *\( P<0.05 \) vs CNTR heart. Representative results
of Western-blot from hearts of 2 mice are shown in B. (C) Expression of ANP and BNP were analyzed by real-time PCR in hearts from (A). * P<0.05 vs CNTR hearts.

Figure 5. Cardiac β-MHC gene expression in control and F1KO mice in response to feeding or insulin stimulation. (A) β-MHC gene expression was measured in the hearts of 10 week-old C57BL/6 mice in a random-fed or 18 h fasting condition, or 1 U/kg insulin I.P. injection for 3 h following the fasting condition. Values represent the mean ± SEM, n=4, *P<0.05 vs with random-fed; # P<0.05 vs fasting. (B) Feeding and insulin activated signaling pathways in the hearts of control mice. Phosphorylation of Akt and MAP kinases were detected by Western-blot, using hearts from 10 week-old mice after 18 h fasting, insulin injection for 3 h, or random-fed conditions. One hundred microgram heart protein lysates were immunoblotted with antibodies against pAkt-S473, pAkt-T308, Akt, pFoxo1-S253, Foxo1, or α-actinin. Representative results of Western-blot from the hearts of 3 mice are presented. (C) β-MHC protein levels were measured by Western-blot from (A). Error bars represent mean ± SEM. n=4, *P<0.05 vs random-fed; # P<0.05 vs fasting. Representative results of Western-blot from the hearts of 2 mice are shown. (D) Protein expression of β-MHC in hearts of F1KO mice following an 18 h fast, random-feeding, or 100 nmol/L insulin injection for 3 h. N.S. indicates no significant difference, n=4-6. Representative results of Western-blot from hearts of 2 mice are shown.
Figure 6. Effects of insulin and Foxo1 on β-MHC gene expression in cardiomyocytes. (A) NRVMs were cultured and pretreated with the kinase inhibitors- wortmannin (100 nmol/L), SP600125 (10 μmol/L), or PD98059(20 μmol/L), for 30 min, prior to 18 h of 100 nmol/L insulin stimulation. Cellular RNA was prepared for real-time analysis. Graphs indicate quantification of mRNA normalized to cyclophilin, from at least 3 independent experiments. Data are expressed as the mean ± SEM, *P<0.05 vs CNTR; # P<0.05 vs insulin group. (B-D) NRVMs and CFs were infected with 25 MOI adenovirus expressing GFP or GFP-Foxo1-wt for 8 h, then serum-starved for 8 h prior to addition of 100 nmol/L insulin for 18 h and mRNA (B) or protein in NRVMs (C-D) was analyzed by real-time PCR or Western-blot, respectively. Data are expressed as the mean ± SEM, *P<0.05 vs GFP; # P<0.05 vs Foxo1-WT. Representative results of Western-blot (C) are shown, in which endogenous Foxo1 (70 kDa) and overexpressed Foxo1 fused with GFP (109 kDa) are indicated. In (D) based on (C), pFoxo1 represents phosphorylation of endogenous Foxo1-S253 normalized by total endogenous Foxo1 in GFP and GFP + insulin group or phosphorylation of overexpressed GFP-Foxo1-S253 normalized by overexpressed total GFP-Foxo1 in Foxo1 wt and Foxo1 wt + insulin group. t-Foxo1 represent the relative total endogenous Foxo1 in GFP and GFP + insulin group or the total overexpressed GFP-Foxo1 normalized by total endogenous Foxo1 in the GFP group. (E) Potential Foxo1 binding sites or insulin response elements are located 9.0 kb upstream of the β-MHC gene transcriptional initiation site and a comparison between mouse and rat is shown. (F) Binding of endogenous Foxo1 in the hearts of wild-type mice to the potential Foxo1 binding site was confirmed by ChIP assay.
Immunoprecipitation of heart chromatin was isolated from fasted control mice with anti-Foxo1 antibody and control IgG. Occupancy of the Foxo1 site in the β-MHC promoter was determined by PCR, in which control immunoprecipitation with non-relevant IgG demonstrates specificity of the assay. Representative results from 3 independent experiments are shown.

Figure 7. Proposed mechanisms of insulin resistant cardiomyopathy by which activated Foxo1 following insulin resistance has key roles in control of metabolic and cardiac dysfunction. IR: insulin resistance; DCM, dilated cardiomyopathy; HCM; hypertrophied cardiomyopathy; β-MHC, β-myosin heavy chain.
**Figure 1**

A) 

Breeding → αMHC-merCremerer

H-DKO-merCremer: Cre\(^+\)/IRS\(^1\)/IRS\(^2\)

H-TKO-merCremer: Cre\(^+\)/IRS\(^1\)/IRS\(^2\)/Foxo\(^1\)

Breeding → Tamoxifen

H-DKO: Cre\(^+\)/IRS\(^1\)/IRS\(^2\)

H-TKO: Cre\(^+\)/IRS\(^1\)/IRS\(^2\)/Foxo\(^1\)

---

B) 

CNTR | H-DKO | H-TKO

IRS1
IRS2
Foxy1
pFoxo1
β-MHC
α-Actinin

---

C) 

Survival (%)

Age of mice (weeks)

Tamoxifen

P < 0.05

---

D) 

mRNA expression

β-MHC  ANP  BNP

CNTR  H-DKO  H-TKO
Figure 2

A. Schematic representation of breeding strategies generating experimental mice. 

B. Bar graph showing mRNA expression levels of β-MHC and α-MHC in different mouse strains.

C. Scatter plot displaying the percentage of EF and FS in control and experimental groups.

D. Additional data showing mRNA expression levels with various treatments.

E. Graph illustrating the effect of HFD on mRNA expression in F1 KO and F1 KO+HFD groups.
Figure 3

**Protein expression**

- **β-MHC**
  - CNTR
  - CNTR+STZ
  - F1 KO
  - F1 KO+STZ

**mRNA expression**

- **β-MHC**
  - CNTR
  - CNTR+STZ
  - F1 KO
  - F1 KO+STZ

**α-MHC**

- CNTR
- CNTR+STZ
- F1 KO
- F1 KO+STZ

**Expressed**

- **β-MHC**
- Foxo1
- α-Actinin

**A**

**B**
Figure 4

A

Protein expression

B

mRNA expression

C

mRNA expression

β-MHC

α-MHC
t-Foxo1

Foxo1

ANP

BNP
Figure 5

A

CNTR hearts

<table>
<thead>
<tr>
<th>mRNA expression</th>
<th>Fed</th>
<th>Fast</th>
<th>Ins 3h</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-MHC mRNA</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

CNTR hearts

- p-Akt-S473
- Akt
- p-Foxo1-S253
- t-Foxo1
- α-Actinin

C

CNTR hearts

<table>
<thead>
<tr>
<th>Protein expression</th>
<th>Fed</th>
<th>Fast</th>
<th>Ins 3h</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-MHC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-Foxo1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

D

F1KO hearts

- β-MHC
- α-Actinin

N.S.
Figure 6

**A**

mRNA expression

<table>
<thead>
<tr>
<th>Condition</th>
<th>β-MHC</th>
<th>α-MHC</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNTR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMSO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ins</td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>Ins + Wort</td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>Ins + SP</td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>Ins + PD</td>
<td>*</td>
<td></td>
</tr>
</tbody>
</table>

**B**

mRNA expression

<table>
<thead>
<tr>
<th>Condition</th>
<th>NRVMs</th>
<th>CFs</th>
</tr>
</thead>
<tbody>
<tr>
<td>GFP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GFP + Ins</td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>Foxo1 wt</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foxo1 wt + Ins</td>
<td>*</td>
<td></td>
</tr>
</tbody>
</table>

**C**

Ins -

GFP

Ins +

GFP + Foxo1 wt

β-MHC

pFoxo1-S253

(109 kDa)

Foxo1 (109 kDa)

p-Foxo1-S253

(70 kDa)

t-Foxo1 (70 kDa)

α-Actinin

**D**

Protein expression

<table>
<thead>
<tr>
<th>Condition</th>
<th>β-MHC</th>
<th>p-Foxo1</th>
<th>t-Foxo1</th>
</tr>
</thead>
<tbody>
<tr>
<td>GFP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GFP + Ins</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Foxo1 wt</td>
<td></td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Foxo1 wt + Ins</td>
<td>*</td>
<td>*</td>
<td>#</td>
</tr>
</tbody>
</table>

**E**

Mouse

Rat

**F**

M Input IgG α-Foxo1

240 bp
PI3K
Δ
Akt

↓

H-DKO (IR)
Db/db (T2DM)

DCM
HCM

Foxo1

↑

Decrease mitochondria
Impair energy metabolism
 Increase apoptosis

↓

Heart dysfunction

β-MHC

↑

Rescue mitochondria
Recover metabolism
Reduce apoptosis

↓

Improved cardiac dysfunction
Activation of Foxo1 by Insulin Resistance Promotes Cardiac Dysfunction and β-Myosin Heavy Chain Gene Expression
Yajuan Qi, Qinglei Zhu, Kebin Zhang, Candice Thomas, Yuxin Wu, Rajesh Kumar, Kenneth M. Baker, Zihui Xu, Shouwen Chen and Shaodong Guo

Circ Heart Fail. published online December 4, 2014;
Circulation: Heart Failure is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2014 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-3289. Online ISSN: 1941-3297

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circheartfailure.ahajournals.org/content/early/2014/12/04/CIRCHEARTFAILURE.114.001457

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Heart Failure can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Heart Failure is online at:
http://circheartfailure.ahajournals.org//subscriptions/